Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (2016 - 2025)

Sutro Biopharma (STRO) has disclosed Shares Outstanding for 10 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.35% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, up 3.35% year-over-year, with the annual reading at $8.6 million for FY2025, 3.35% up from the prior year.
  • Shares Outstanding hit $8.6 million in Q4 2025 for Sutro Biopharma, down from $85.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $85.1 million in Q3 2025 to a low of $482738.0 in Q1 2024.
  • Historically, Shares Outstanding has averaged $50.8 million across 5 years, with a median of $51.7 million in 2022.
  • Biggest five-year swings in Shares Outstanding: tumbled 99.2% in 2024 and later surged 17373.05% in 2025.
  • Year by year, Shares Outstanding stood at $46.3 million in 2021, then grew by 24.12% to $57.5 million in 2022, then plummeted by 89.3% to $6.2 million in 2023, then surged by 34.96% to $8.3 million in 2024, then rose by 3.35% to $8.6 million in 2025.
  • Business Quant data shows Shares Outstanding for STRO at $8.6 million in Q4 2025, $85.1 million in Q3 2025, and $84.7 million in Q2 2025.